Group 1 - The core point of the article is that Guangdong Heng Rui Medicine Co., Ltd. has initiated a Phase IIa clinical trial for SHR-1905 injection, targeting moderate to severe atopic dermatitis patients, with the trial registered under CTR20253993 and first publicized on October 15, 2025 [1][2]. Group 2 - The clinical trial aims to evaluate the efficacy of SHR-1905 injection in patients with moderate to severe atopic dermatitis, with primary endpoints including the percentage change in the Eczema Area and Severity Index (EASI) from baseline [1]. - Secondary endpoints include the proportion of overall assessments by researchers (IGA), changes in the Worst Itch Numeric Rating Scale (WI-NRS), EASI-related achievement rates, changes in body surface area (BSA) affected by atopic dermatitis, changes in the SCORAD score, and adverse events [1]. - The trial is currently ongoing with a target enrollment of 20 participants, and recruitment has not yet started [2].
广东恒瑞SHR - 1905注射液启动II期临床 适应症为中重度特应性皮炎
Xin Lang Cai Jing·2025-10-15 05:13